Table 3.
Outcomes of HSCT patients with rhinovirus infectious disease and matched controls
| Cases (n=47) | Controls (n=94) | P-value | |
|---|---|---|---|
| Death or hospice discharge | 17.0% (8) | 14.9% (14) | 0.74 |
| Relapse of malignancy | 17.0% (8) | 19.2% (18) | 0.76 |
| Recurrent hospitalization | 46.8% (22) | 24.5% (23) | 0.007 |
| Recurrent hospitalization from infection | 34.0% (16) | 14.9% (14) | 0.015 |
| Number of recurrent hospitalizations in those rehospitalized | 1.4 ± 0.6 | 1.8 ± 0.9 | 0.06 |
| ICU admissions and/or mechanical ventilation | 10.6% (5) | 12.8% (12) | 0.72 |
| Other infectious syndromes | |||
| Pneumonia | 25.5% (12) | 13.8% (13) | 0.09 |
| Neutropenic fever | 12.8% (6) | 6.4% (6) | 0.20 |
| C. difficile | 6.4% (3) | 5.3% (5) | 1.0 |
| Other URID | 17.0% (8) | 17.0% (16) | 1.0 |
| Bacteremia | 23.4% (11) | 10.6% (10) | 0.076 |
| CMV viremia | 12.8% (6) | 20.2% (19) | 0.35 |
| EBV viremia | 2.1% (1) | 4.3% (4) | 0.67 |
| GVHD | |||
| Any GVHD | 73.1% (19) | 61.5% (32) | 0.45 |
| Skin GVHD | 50.0% (13) | 44.2% (23) | 0.64 |
| Liver GVHD | 15.4% (4) | 13.5% (7) | 1.0 |
| Other GVHD | 3.9% (1) | 9.6% (5) | 0.66 |
HSCT= hematopoietic Stem cell transplant, ICU=Intensive care unit, URID=Upper respiratory tract infectious disease, CMV=Cytomegalovirus, EBV=Epstein-Barr virus, GVHD=Graft vs. host disease